Seminars in Oncology
Volume 33, Supplement 3 , Pages 11-16, February 2006

Clinical Experience With Denileukin Diftitox (ONTAK)

  • Francine Foss

      Affiliations

    • Corresponding Author InformationAddress correspondence and reprint requests to Francine Foss, MD, Hematologic Malignancies, Medical Oncology, Yale Cancer Center, 333 Cedar St, New Haven, CT 06520

Yale Cancer Center, New Haven, CT

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This supplement was supported by an unrestricted educational grant from Zeneus Pharma Ltd.

 Prof Foss is a member of the speakers’ bureau for Ligand Pharmaceuticals.

PII: S0093-7754(05)00511-7

doi:10.1053/j.seminoncol.2005.12.017

Seminars in Oncology
Volume 33, Supplement 3 , Pages 11-16, February 2006

Article Tools

* Image Usage & Resolution